Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Esophageal Carcinoma, Lung Non-Small Cell Carcinoma
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
This trial studies how well dyadic yoga intervention works in improving physical performance and quality of life in patients with stage I-IV non-small cell lung or esophageal cancer undergoing radiotherapy and their caregivers.
- Conditions
- Esophageal Carcinoma, Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8
- Trial name
- NCT03948100
- Testing
- Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD
Lung Cancer
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280735
- Testing
- carboplatin, docetaxel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well CCI-779 works in treating patients with stage IIIB non small cell lung cancer (with pleural effusion) or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00079235
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or…
- Trial name
- NCT00005989
- Testing
- tipifarnib
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
Non-Small Cell Lung Cancer
Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment
Study Rationale: There is increasing evidence that erlotinib improves overall survival in selected patients with stage IIIB-IV NSCLC.
- Trial name
- NCT00840125
- Testing
- erlotinib, docetaxel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Meir Medical Center
Non Small Cell Lung Cancer
MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Lung cancer is one of the most prevalent and lethal neoplasias in the world. Currently used chemotherapy regimens have been disappointing in improving overall survival.
- Trial name
- NCT01628471
- Testing
- decitabine in combination with genistein
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Uman Pharma
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- ANVIL (NCT02595944)
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 884 sites in United States
- Volunteers
- 903 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer
This study combines nelfinavir (NFV) with radiation therapy and chemotherapy as a treatment for non-small cell lung cancer (NSCLC) who are considered candidates for pre-operative treatment.
- Trial name
- NCT00791336
- Testing
- Nelfinavir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Iowa
Lung Cancer
Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075517
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Lung, Non-small Cell Lung Cancer
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Hsp90 inhibitor AUY922 and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01259089
- Testing
- erlotinib hydrochloride, Hsp90 inhibitor AUY922, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Lung Cancer
DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have previously…
- Trial name
- NCT00005091
- Testing
- exatecan mesylate
- Where
- 6 sites in Finland, Germany and 3 more
- Sponsor
- Daiichi Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7
Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer
This pilot clinical trial studies the effects of stereotactic body radiation therapy followed by surgery in treating patients with stage I-IIIA non-small cell lung cancer.
- Conditions
- Stage I Non-Small Cell Lung Cancer AJCC v7, Stage IA Non-Small Cell Lung Carcinoma AJCC v7, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT03348748
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Non-small Cell Lung Cancer
Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
To investigate the efficacy of carbon ion therapy for stage Ia-IIa primary peripheral non-small cell lung cancer (NSCLC). The primary endpoint was progression-free survival (PFS), and the secondary endpoint was local control…
- Trial name
- NCT05613452
- Testing
- Carbon ion beam radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune…
- Conditions
- Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer
- Trial name
- NCT00019006
- Testing
- Detox-B adjuvant, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- KontRASt-03 (NCT05358249)
- Testing
- JDQ443, trametinib, Ribociclib
- Where
- 13 sites in United States, Belgium and 6 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
NSCLC
Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)
Despite recent advances in the treatment of NSCLC overall survival within these patients remains dismal and there is yet an unmet medical need for additional treatment options.
- Trial name
- NCT01368848
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 3 sites in Austria
- Volunteers
- 7 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to…
- Trial name
- NCT06031688
- Testing
- Biospecimen Collection, Computed Tomography, Lymphoscintigraphy
- Where
- 278 sites in United States
- Volunteers
- 56 people
- Sponsor
- SWOG Cancer Research Network
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
The investigators propose this phase I/II study to use weekly Nab-Paclitaxel (Abraxane) and carboplatin with concurrent radiation in local-regionally advanced lung cancer.
- Trial name
- NCT01757288
- Testing
- NAB-PACLITAXEL, PACLITAXEL
- Where
- 5 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Texas Southwestern Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.